source
- AbCellera reports striking Phase 2 results for hot-flash treatment, shares jump 31%AbCellera Biologics announced positive Phase 2 data for its neurokinin-3 receptor antagonist aimed at relieving vasomotor symptoms such as hot flashes. The company described the results as strikin…
- Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to VertexSionna Therapeutics said its lead cystic fibrosis drug did not meet primary endpoints in an early-stage study, marking a setback for the company. The result reduces expectations that Sionna could…